Altamira Therapeutics Stock Alpha and Beta Analysis
| CYTO Stock | USD 0.40 0.02 4.17% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Altamira Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Altamira Therapeutics over a specified time horizon. Remember, high Altamira Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Altamira Therapeutics' market risk premium analysis include:
Beta 0.082 | Alpha (1.07) | Risk 4.8 | Sharpe Ratio (0.24) | Expected Return (1.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Altamira |
Altamira Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Altamira Therapeutics market risk premium is the additional return an investor will receive from holding Altamira Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Altamira Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Altamira Therapeutics' performance over market.| α | -1.07 | β | 0.08 |
Altamira Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Altamira Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Altamira Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Altamira Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Altamira Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Altamira Therapeutics shares will generate the highest return on investment. By understating and applying Altamira Therapeutics stock market price indicators, traders can identify Altamira Therapeutics position entry and exit signals to maximize returns.
Altamira Therapeutics Return and Market Media
The median price of Altamira Therapeutics for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 0.62 with a coefficient of variation of 25.63. The daily time series for the period is distributed with a sample standard deviation of 0.16, arithmetic mean of 0.63, and mean deviation of 0.13. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Altamira Therapeutics Announces Pricing of up to 12.0 Million Public Offering | 09/17/2024 |
2 | Altamira Therapeutics Announces Closing of up to 12.0 Million Public Offering | 09/19/2024 |
3 | Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia | 09/23/2024 |
4 | Altamira Therapeutics Ltd Q2 2024 Earnings Call Transcript Highlights Key Financial and ... | 09/25/2024 |
5 | Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray | 09/27/2024 |
6 | Disposition of 10000 shares by Carter Stephen of Altamira Therapeutics at 0.62 subject to Rule 16b-3 | 10/04/2024 |
7 | CYTO stock plunges to 52-week low, hitting 0.57 amid market challenges - Investing.com | 10/21/2024 |
8 | Acquisition by Lokay Kevin G of 10000 shares of Altamira Therapeutics at 11.5 subject to Rule 16b-3 | 11/08/2024 |
9 | ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeutics Ltd | 11/15/2024 |
About Altamira Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Altamira or other stocks. Alpha measures the amount that position in Altamira Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 0.63 | 0.3 | 0.35 | 0.52 | Days Of Inventory On Hand | 136.71 | 2.94 | 3.39 | 3.22 |
Altamira Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Altamira Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Altamira Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Altamira Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Altamira Therapeutics. Please utilize our Beneish M Score to check the likelihood of Altamira Therapeutics' management manipulating its earnings.
| 21st of May 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Altamira Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Altamira Therapeutics Backtesting, Altamira Therapeutics Valuation, Altamira Therapeutics Correlation, Altamira Therapeutics Hype Analysis, Altamira Therapeutics Volatility, Altamira Therapeutics History and analyze Altamira Therapeutics Performance. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Altamira Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.